// App-Quantinova.ai

863 : Alternative Super-Enhancer States Determine MYC Sensitivity to Notch and Brd4 Inhibitors in T Lymphoblastic Leukemia/Lymphoma

Researchers

Presenter

  • Hongfang Wang

Principal Investigators

  • Yumi Yashiro-Ohtani

  • Chongzhi Zang

  • Yinling Joey Wong

  • Will Bailis

  • Birgit Knoechel

  • Bradley Bernstein

  • Steve Blacklow

  • X. Shirley Liu

  • Warren S. Pear

  • Jon C Aster

Medical Centers

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

  • The Broad Institute, Massachusetts General Hospital, Boston, MA

  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Boston Children's Hospital, Boston, MA

Locations

  • United States

Companies

  • Molecular Pharmacolo

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Lymphomas

Biomarkers

  • Neurogenic locus notch homolog protein 1

  • cMYC

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved